Literature DB >> 7586953

Changes in plasma warfarin levels and variations in steady-state prothrombin times.

R H White1, H Zhou, P Romano, D Mungall.   

Abstract

OBJECTIVE: To determine the relative contribution of changes in the plasma warfarin level to variation in the serial steady-state prothrombin times.
METHODS: This was a prospective observational cohort study performed at two outpatient anticoagulation clinics. Serial prothrombin times and paired plasma total warfarin levels were determined in a convenience sample of otherwise healthy patients who required long-term oral anticoagulation therapy with warfarin.
RESULTS: Serial measurements were obtained from 129 patients, 60 of whom provided three or more serial samples. Analysis of covariance showed a highly significant (p = 0.0001) relationship between the anticoagulant effect and the logarithm of the warfarin concentration (R2 = 0.75), with 15.3% of the total variance attributable to the effect of warfarin and 31.1% attributable to individual variation in sensitivity to warfarin. In an analysis of the subjects who had three or more serial measurements, the mean weighted correlation coefficient for the relationship between the logarithm of the warfarin concentration and the anticoagulant response varied widely, from strongly negative to strongly positive, and as the range of observed prothrombin times increased, stronger positive correlation was observed.
CONCLUSIONS: In this cohort, the plasma warfarin level was a strong predictor of observed changes in serial prothrombin time measurements. However, the correlation between clotting times and warfarin levels varied widely among subjects, particularly when the range of observed prothrombin times was moderate. This suggests that in these subjects, other factors, such as measurement error or pharmacodynamic changes, played a major role.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586953     DOI: 10.1016/0009-9236(95)90179-5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Authors:  Richard A Faaij; Jacobus Burggraaf; Rik C Schoemaker; Rik de Greef; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Authors:  R A Faaij; J Burggraaf; R C Schoemaker; R G M Van Amsterdam; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

3.  In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.

Authors:  Aaron D Baldwin; Karyn G Robinson; Jaimee L Militar; Christopher D Derby; Kristi L Kiick; Robert E Akins
Journal:  J Biomed Mater Res A       Date:  2012-05-21       Impact factor: 4.396

4.  Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study.

Authors:  Terhi Launiainen; Antti Sajantila; Ilpo Rasanen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2009-09-25       Impact factor: 2.953

5.  Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.

Authors:  Nicole Mittmann; Paul I Oh; Scott E Walker; William R Bartle
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Effects of formulation types on pharmacodynamics of warfarin in patients with cerebral infarction and dysphagia.

Authors:  Young-Ji Kim; Jong-Woo Jeong; Youngshin Song; Tae-Sung Koo
Journal:  Clin Pharmacol       Date:  2019-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.